Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.
Manouk K BosS W LamG MottaJ C A HelmijrC M BeaufortE de JongeJ W M MartensE BovenM P H M JansenA JagerS SleijferPublished in: Breast cancer research and treatment (2023)
Presence of ESR1 mutations in baseline ctDNA might not be associated with inferior PFS and OS in advanced breast cancer patients treated with paclitaxel/bevacizumab.